June 3, 2025 11:27 AM EDTUpdated 01:11 PM
Deals
Manufacturing

Agenus quick­ly ex­its CD­MO busi­ness by sell­ing as­sets to Zy­dus for $75M up­front

Anna Brown

News Reporter

Agenus is di­vest­ing its bi­o­log­ics CD­MO busi­ness, which it launched on­ly six months ago, to In­di­an drug­mak­er Zy­dus Life­sciences …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Strug­gling biotechs suc­cumb to icy mar­ket, as mon­ey dries up and clin­i­cal bets don’t pay off

In a first, Sarep­ta an­nounces plat­form tech­nol­o­gy des­ig­na­tion for gene ther­a­py vec­tor

Anap­tys­Bio de­scribes ‘JAK-like’ ef­fi­ca­cy for PD-1 drug in rheuma­toid arthri­tis

Lil­ly makes a move for long-act­ing in­cretins in tech deal with Swedish biotech

Phar­ma com­pa­nies rush in to buy what they hope will ri­val Keytru­da

sponsored

Cy­ti­va and Eu­rek­aBio form strate­gic part­ner­ship to ad­vance lentivi­ral vec­tor man­u­fac­tur­ing for cell and gene ther­a­py ...

A service from the Financial Times